このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Myriad Genetics 将来の成長

Future 基準チェック /16

Myriad Genetics利益と収益がそれぞれ年間66.8%と6.8%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に3.5% 65%なると予測されています。

主要情報

66.8%

収益成長率

65.0%

EPS成長率

Biotechs 収益成長	31.4%
収益成長率	6.8%
将来の株主資本利益率	3.5%
アナリストカバレッジ	Good
最終更新日	03 Jun 2024

今後の成長に関する最新情報

Recent updates

業績と収益の成長予測

DB:MYD - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	959	-30	39	57	8
12/31/2025	898	-69	16	36	12
12/31/2024	832	-98	4	8	12
3/31/2024	774	-235	-155	-96	N/A
12/31/2023	753	-263	-184	-111	N/A
9/30/2023	734	-274	-138	-63	N/A
6/30/2023	699	-248	-119	-44	N/A
3/31/2023	695	-146	-155	-93	N/A
12/31/2022	678	-112	-152	-106	N/A
9/30/2022	661	-77	-143	-108	N/A
6/30/2022	672	-18	-164	-145	N/A
3/31/2022	682	-8	-117	-100	N/A
12/31/2021	691	-27	1	19	N/A
9/30/2021	684	-57	-7	14	N/A
6/30/2021	662	-97	-26	-6	N/A
3/31/2021	566	-148	11	28	N/A
12/31/2020	557	-224	-40	-27	N/A
9/30/2020	598	-194	-25	-14	N/A
6/30/2020	639	-199	51	61	N/A
3/31/2020	761	-148	53	62	N/A
12/31/2019	813	-26	43	52	N/A
9/30/2019	835	-15	83	92	N/A
6/30/2019	851	5	75	84	N/A
3/31/2019	830	23	91	100	N/A
12/31/2018	796	26	96	105	N/A
9/30/2018	767	54	92	100	N/A
6/30/2018	744	133	108	116	N/A
3/31/2018	749	130	97	105	N/A
12/31/2017	763	126	N/A	134	N/A
9/30/2017	771	101	N/A	133	N/A
6/30/2017	729	17	N/A	106	N/A
3/31/2017	757	32	N/A	108	N/A
12/31/2016	751	63	N/A	113	N/A
9/30/2016	748	94	N/A	134	N/A
6/30/2016	741	117	N/A	166	N/A
3/31/2016	757	121	N/A	179	N/A
12/31/2015	747	108	N/A	163	N/A
9/30/2015	738	95	N/A	163	N/A
6/30/2015	723	80	N/A	141	N/A
3/31/2015	722	95	N/A	130	N/A
12/31/2014	725	110	N/A	112	N/A
9/30/2014	745	137	N/A	107	N/A
6/30/2014	778	176	N/A	190	N/A
3/31/2014	764	187	N/A	212	N/A
12/31/2013	737	188	N/A	238	N/A
9/30/2013	682	172	N/A	213	N/A
6/30/2013	613	147	N/A	174	N/A

アナリストによる今後の成長予測

収入対貯蓄率: MYD今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: MYD今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: MYD今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: MYDの収益 ( 6.8% ) German市場 ( 5.1% ) よりも速いペースで成長すると予測されています。

高い収益成長: MYDの収益 ( 6.8% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: MYDの自己資本利益率は、3年後には低くなると予測されています ( 3.5 %)。

Myriad Genetics 将来の成長

Future 基準チェック /16

主要情報

今後の成長に関する最新情報

Myriad Genetics, Inc. Reiterates Earnings Guidance for the Full Year 2024

Myriad Genetics, Inc. Updates Revenue Guidance for the Fiscal Year 2024

Myriad Genetics, Inc. Provides Revenue Guidance for the First Quarter 2024

Myriad Genetics, Inc. Provides Financial Guidance for 2023 and 2024

Myriad Genetics, Inc. Provides Earnings Guidance for the Year 2023

Myriad Genetics, Inc. Revises Earnings Guidance for the Full Year of 2023

Recent updates

CEO, President & Director recently sold €5.3m worth of stock

Myriad Genetics, Inc. Reiterates Earnings Guidance for the Full Year 2024

First quarter 2024 earnings released: US$0.29 loss per share (vs US$0.67 loss in 1Q 2023)

Myriad Genetics, Inc. to Report Q1, 2024 Results on May 07, 2024

Myriad Genetics, Inc. Updates Revenue Guidance for the Fiscal Year 2024

Myriad Genetics, Inc. Provides Revenue Guidance for the First Quarter 2024

Full year 2023 earnings released: US$3.18 loss per share (vs US$1.39 loss in FY 2022)

Myriad Genetics, Inc. to Report Q4, 2023 Results on Feb 27, 2024

Myriad Genetics, Inc. Appoints George Daneker as President and Chief Clinical Officer of Oncology, Effective March 18, 2024

Myriad Genetics, Inc. (NasdaqGS:MYGN) agreed to acquire Select assets of Intermountain Precision Genomics.

Myriad Genetics, Inc. Announces Chief Financial Officer Changes

Myriad Genetics, Inc. has completed a Follow-on Equity Offering in the amount of $109.999996 million.

New minor risk - Shareholder dilution

Myriad Genetics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Myriad Genetics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Myriad Genetics, Inc. Provides Financial Guidance for 2023 and 2024

Third quarter 2023 earnings released: US$0.75 loss per share (vs US$0.43 loss in 3Q 2022)

Myriad Genetics, Inc. Appoints Samraat S. Raha as Chief Operating Officer, Effective as of December 11, 2023

Myriad Genetics Appoints Sam Raha as Chief Operating Officer, Effective December 11, 2023

Myriad Genetics, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Bernstein Litowitz Berger & Grossmann LLP Proposes Settlement of Class Action Involving Persons Who Purchased or Acquired Myriad Genetics, Inc. Common Stock

Insufficient new directors

Myriad Genetics Announces Enhancements to the Genesight® Test to Personalize Mental Health Medication Treatment Decisions Based on Smoking Status

Myriad Genetics, Inc. Provides Earnings Guidance for the Year 2023

Second quarter 2023 earnings released: US$1.42 loss per share (vs US$0.17 loss in 2Q 2022)

Myriad Genetics, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Myriad Genetics, Inc. Announces Inclusion of Breast Density to Myrisk(R) with Riskscore(R) Breast Cancer Risk Assessment

Myriad Genetics, Inc. Appoints Adam Brufsky as Scientific Advisor

Myriad Genetics, Inc. Revises Earnings Guidance for the Full Year of 2023

First quarter 2023 earnings released: US$0.67 loss per share (vs US$0.26 loss in 1Q 2022)

Full year 2022 earnings released: US$1.39 loss per share (vs US$0.35 loss in FY 2021)

Myriad Genetics, Inc. Hires Senior Leaders to Advance Commercial Growth Plans

Myriad Genetics, Inc. announces Patient Outcomes Study Shows RiskScore Leads to More Accurate Breast Cancer Risk Prediction than Standard-of-Care Risk Model

High number of new directors

Myriad Genetics Announces Urosuite™, an Industry-First Suite of Genetic Tests for Prostate Cancer, Giving Urologists Access to Timely, Data-Driven Medical Information

Third quarter 2022 earnings released: US$0.43 loss per share (vs US$0.31 profit in 3Q 2021)

Myriad Genetics, Inc. (NasdaqGS:MYGN) acquired Gateway Genomics, LLC for approximately $110 million.

Myriad Genetics, Inc. Elects Paul M. Bisaro as New Board Member

High number of new directors

Myriad Genetics, Inc. to Report Q3, 2022 Results on Nov 01, 2022

Myriad Genetics Receives Expanded Coverage in Japan for Use of BRACAnalysis® Diagnostic System as a Companion Diagnostic for Lynparza® in Early-Stage Breast Cancer

Second quarter 2022 earnings released: US$0.17 loss per share (vs US$0.061 loss in 2Q 2021)

Myriad Genetics, Inc. Provides Earnings Guidance for the Year 2022

Myriad Genetics, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Myriad Genetics, Inc. Announces the Resignation of Dennis Langer as Director

Myriad Genetics, Inc. Announces Executive Changes

Myriad Genetics Showcases Advancements in Precision Medicine with Recent Oncology Portfolio Expansion and New Data Presentations at ASCO 2022

First quarter 2022 earnings released: US$0.26 loss per share (vs US$0.52 loss in 1Q 2021)

Myriad Genetics, Inc. Provides Earnings Guidance for the Fiscal Year 2022

High number of new directors

Myriad Genetics, Inc., Annual General Meeting, Jun 02, 2022

Myriad Genetics, Inc. Settles the Qui Tam Lawsuit with STF, LLC

Forecast to breakeven in 2024

Myriad Genetics, Inc. Reiterates Earnings Guidance for the Fiscal Year 2022

Investor sentiment deteriorated over the past week

Myriad Genetics, Inc. to Report Q4, 2021 Results on Feb 24, 2022

Myriad Genetics, Inc. Provides Earnings Guidance for the Year 2022

Laboratory Corporation of America Holdings (NYSE:LH) completed the acquisition of Autoimmune’s Vectra Testing Business from Myriad Genetics, Inc. (NasdaqGS:MYGN).

Independent Chair of the Board recently sold €529k worth of stock

Myriad Genetics, Inc. Reports Goodwill and Long-Lived Asset Impairment Charges for the Second Quarter Ended June 30, 2021

Myriad Genetics, Inc. Launches New Version of its MyRisk Hereditary Cancer Test

Q2 Solutions LLC completed the acquisition of Myriad RBM, Inc. from Myriad Genetics, Inc. (NasdaqGS:MYGN).

Q2 Solutions LLC signed a definitive agreement to acquire Myriad RBM, Inc. from Myriad Genetics, Inc. (NasdaqGS:MYGN) for approximately $200 million.

Myriad Genetics, Inc. to Share New Data at 2021 Asco Validating Personalized Breast Cancer Risk Assessments for Women of All Ancestries

Myriad Genetics, Inc. Not to Provide Financial Guidance for the Quarter Ending June 30, 2021 or Fiscal Year 2021

Castle Biosciences, Inc. (NasdaqGM:CSTL) signed a definitive agreement to acquire Myriad myPath Melanoma, LLC from Myriad Genetics, Inc. (NasdaqGS:MYGN) for $32.5 million.

Castle Biosciences, Inc. (NasdaqGM:CSTL) signed a definitive agreement to acquire Myriad myPath, LLC from Myriad Genetics, Inc. (NasdaqGS:MYGN) for $32.5 million,

Bragar Eagel & Squire, P.C. Announces the Shareholder Class Action Against Myriad Genetics, Inc. Survives Motion to Dismiss and Encourages Long-term Investors to Contact the Firm

Myriad Genetics Joins Forces with Intermountain Precision Genomics for A Comprehensive Offering of Germline and Somatic Tumor Testing Services